INS and metabolic dysfunction-associated steatotic liver disease: Pharmacological activation of PPARγ improves insulin resistance in diabetes and has been reported to decrease liver damage in NAFLD by restoring adipose tissue insulin sensitivity, decreasing FFA flux to the liver [84, 85].